Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Drug approvals
Lung cancer drug approvals: the latest news
In this ongoing roundup article, we cover the latest global drug approvals for lung cancer. Read on to find out what new therapeutic options are emerging for thoracic malignancies. Imdylltra® (tarltamab) Indication: certain adult SCLC patients Approving body: MHRA Approved: 31st December 2024 December saw the MHRA approve Amgen's (CA, USA) tarlatamab, an antieoplastic agent that kills rapidly dividing cancer cells, for metastatic SCLC patients for whom two previous lines of treatment have failed.
What does the US FDA approval of Anktiva signify for bladder cancer care?
The US FDA recently approved Anktiva® (N-803), a first-of-its-kind immunotherapy, in combination with BCG for the treatment of non-muscle-invasive bladder cancer (NMIBC). In this interview, we speak with Karim Chamie (UCLA, CA, USA) to discover the importance of IL-15 in NMIBC and how this links with Anktiva’s mechanism of action. Chamie also provides a bitesize breakdown of key results from the trial evaluating its efficacy and safety – the QUILT 3.032 study.
US FDA drug approvals in oncology: the latest news
In our ongoing roundup article, we cover the latest oncology drugs being approved by the US FDA. Read on to discover what new therapeutic options are emerging for a range of cancer types.
Twice as NICE: CAR-T therapies recommended for treatment of aggressive blood cancer
In final draft guidance, the National Institute for Health and Care Excellence (NICE) recommended two new personalized CAR-T therapies for use within the Cancer Drugs Fund (CDF). The treatments are set to benefit approximately 600 people in England, with aggressive forms of blood cancer, per year. The treatment options both come from Kite Pharma (CA, USA), a company who have existed at the forefront of CAR-T immunotherapy for over a decade.
Hope on the horizon: first immunotherapy drug approved for cervical cancer patients in the UK
The Cancer Drugs Fund (CDF) is set to provide the first immunotherapy drug for advanced cervical cancer patients in the UK, as NICE published its final draft guidance. The availability of this new treatment option for cervical cancer patients marks a significant milestone, offering hope to those who previously had limited options beyond standard care.
Top 3 oncology drug approvals January: Yescarta®, Ninlaro® & Brukinsa®
The advent of the new year has brought with it a plethora of new treatment options in the hematologic oncology arena as several drugs received new designations. Read our full roundup below to find out about expanses in therapeutic choices for multiple myeloma, leukemia and lymphoma subtypes.
NICE approves ixazomib in combination with lenalidomide-dexamethasone to treat relapsed or refractory multiple myeloma
The National Institute for Health and Care Excellence (NICE) published a guidance document recommending the use of ixazomib (brand name Ninlaro®) in combination with lenalidomide and dexamethasone in patients with refractory or relapsed multiple myeloma. It is estimated that approximately 2000 individuals will be in line to benefit from the new oral therapy following the release of the NICE guidance and is recommended for those who have previously had 2 or 3 treatments.
NICE endorses Tepmetko® as first and only targeted oral treatment for METex14 mutated NSCLC
The National Institute for Health and Care Excellence (NICE) has endorsed Tepmetko® (tepotinib) for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with METex14 skipping alterations. In the VISION study, tepotinib demonstrated significant benefits including slowing disease progression and extending survival. NSCLC makes up 87% of lung cancer cases with 3–4% of advanced NSCLC cases displaying METex14 skipping alterations.
Top 3 drug approvals in oncology in March 2022: Sotorasib, Opdualag™ and Pluvicto™
As we eagerly await presentations and the exciting data sure to be presented at the the AACR 2022 Annual Meeting (8–13 April, LA, USA), we are looking back at what drugs have been approved this past month for various cancer indications. Read about two US FDA approvals as well as an approval from across the pond in the UK.
Top 3 advancements in oncology: February 2022
February has been a busy month for the National Institute for Health and Care Excellence in the UK! It has provided guidance recommending both a PARP inhibitor and a tyrosine kinase inhibitor, as well as endorsing four new devices for safer prostate cancer diagnosis. Find out more by checking out the summary below.
NICE recommends the PARP inhibitor niraparib for ovarian cancer treatment via the NHS
A PARP inhibitor, termed Zejula® (niraparib), has been endorsed for routine use in the NHS by the National Institute for Health Care and Excellence (NICE, UK) to treat some forms of ovarian, peritoneal or fallopian tube cancer. Niraparib is a capsule to be taken once daily. It will be available for those with various forms of fallopian tube, ovarian or peritoneal cancer who meet specific criteria.
Top 3 cancer drug approvals: January 2022
To hail in the start of the new year we are highlighting three cancer drug approvals that have occurred over the past month. Read on to find out what advancements have been made in treatment options for NSCLC both in China and the UK, as well as a US FDA drug approval for melanoma.
NICE recommend Osimertinib (Tagrisso®) for EGFR+ Stage 1b-3A NSCLC within the Cancer Drugs Fund
NICE recently published final draft guidance recommending osimertinib (Tagrisso®), a 3rd generation EGFR-TKI, for use in early-stage EGFR T790M mutation-positive NSCLC patients who have progressed on previous EGFR-targeted therapies and who have had their tumor surgically resected. Surgical removal of tumors is the preferred treatment option for many patients with early-stage NSCLC because it has a relatively high potential for curing the disease.
Top 3 drug approvals in November 2021 - Fyarro™, Tagrisso® and Retsevmo
As we draw closer to the end of 2021, we are looking at what key drugs have been approved for cancer in November. Highlights from the past month include the approval of drugs by the USA FDA and NICE for rare diseases, addressing unmet needs and in turn, improving the prognosis for patients with the conditions. Fyarro™ (mobocertinib) Approved: 23 November 2021 Company: Aadi Bioscience, Inc.
Opdivo® plus Yervoy® approved by the MHRA for inoperable malignant pleural mesothelioma
The Medicines and Healthcare products Regulatory Agency (MHRA) have approved Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for first-line treatment of inoperable pleural mesothelioma (MPM) in the UK. Pleural mesothelioma is rare but devastating cancer affecting the pleural tissue covering the lungs. Construction and industry workers are at greater risk of developing MPM as asbestos exposure is implicated in 80% of cases.
UK’s NICE recommend pemigatinib (Pemazyre®) for FGFR2+ cholangiocarcinoma
The UK’s National Institute for Health and Care Excellence (NICE) recently published final draft guidance recommending pemigatinib (Pemazyre®) for the treatment of locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement. The treatment is an option for adults whose cancer has progressed after chemotherapy.
US FDA approves Keytruda® combined with trastuzumab and chemotherapy for gastric cancer
The US FDA have approved Keytruda® (pembrolizumab), an anti-PD-1 therapy, in combination with trastuzumab and chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
What does the US FDA approval of trilaciclib mean for oncologists and their patients?
In this interview we speak with Jared Weiss from UNC’s Lineberger Comprehensive Cancer Center (NC, USA) about challenges associated with treating small cell lung cancer (SCLC) and his thoughts on what the recent US FDA approval of trilaciclib, for the treatment of extensive SCLC patients to reduce chemotherapy-induced bone marrow suppression, could mean for SCLC patients. Please introduce yourself and tell us about your career to date. My name is Jared Weiss.
Real World Evidence Solutions Market Size, Trends and Forecast, 2024-2034
What's Covered in Full Report Market Size & Share Analysis Market Trends Analysis Market Players Analysis Define Business Strategies Import & Export Data Growth Driving Factors Future Commercial Potential Regional & Country Wise Growth Insights Looks good! Please enter your full name. Looks good! Please provide a valid email address. Looks good! Please select a country. Looks good! Please enter your contact number. Looks good! Please enter your company name. * These fields are required.
Isatuximab recommended for approval in multiple myeloma – Oncology Central
The European Medicines Agency’s Committee for Medicinal Products for Human Use issued positive opinion for second indication for isatuximab in combination with carfilzomib and dexamethasone (Kd) for multiple myeloma (MM) who have received at least one prior therapy. MM is the second most common hematologic malignancy and despite available treatments, remains an incurable malignancy associated with significant patient burden. Since MM does not have a cure, most patients will relapse.
lenvatinib plus pembrolizumab for solid tumors
The latest Clinical Trial Evaluation published in Future Oncology discusses the LEAP clinical development program, which is investigating lenvatinib plus pembrolizumab with or without chemotherapy in patients with several solid tumor types who currently have limited available therapies. The LEAP program is based on the promising results from Study 111/KEYNOTE-146 and Study 116/KEYNOTE-524.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Drug
Contact Drug, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack